NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 BETA DRUGS LIMITED – 21ST ANNUAL REPORT FY 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Consolidated Total Revenue: INR 384.8 crores | 2026-09-05 |
| Investor presentation BETA DRUGS LTD – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 3,848 Mn; Q1-FY27 Revenue: INR 1,255 Mn (25.2% YoY growth) • 5-Year Revenue C | 2026-07-27 |
| Quarterly results · Q1 FY27 BETA DRUGS LIMITED – Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS CONSOLIDATED RESULTS (Q1 ended 30 June 2026) • Total Revenue: Rs 1,27,13,21,690 | 2026-07-23 |
| Q4 FY26 earnings call BETA DRUGS LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Net revenue grew from INR 368 crores (FY25) to INR 396 crores (FY26) – 7.6% growth | 2026-05-22 |
| Investor presentation · Q4 FY26 BETA DRUGS LIMITED – FY26 ANNUAL RESULTS SUMMARY HEADLINE NUMBERS • Total FY26 Revenue: INR 385 Crores (Branded 140 Cr + CDMO 149 Cr + Exports 71 Cr | 2026-05-15 |
| Quarterly results · Q4 FY26 BETA DRUGS LIMITED - FY26 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Total Revenue FY26: Rs 396.0 crores (7.4% growth vs Rs 368.8 crores in F | 2026-05-14 |
| Quarterly results · Q3 FY26 BETA DRUGS LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Total Revenues: INR 89.58 Crores • Q3 EBITDA: INR 19.28 Crores (22% margin) • Q3 Pro | 2026-02-14 |
| Q2 FY26 earnings call BETA DRUGS LIMITED – H1 FY'26 SUMMARY HEADLINE NUMBERS • Total sales: Rs. 204 crores vs Rs. 180 crores in H1 FY'25 (13% growth) • EBITDA: Rs. 47 cro | 2025-11-13 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completion of acquisition of shares in Nivian Lifesciences Private Limited Beta Drugs Limited has completed its acquisition of shares in Nivian Lifesciences Private Limited. This announcement was made under regulatory requirements that mandate listed companies to d | 2026-05-25 |
| Acquisition of 66.09% stake in Nivian Lifesciences Private Limited Beta Drugs Limited has submitted a revised update regarding its acquisition of a 66.09% majority stake in Nivian Lifesciences Private Limited to the stock exchange. Key Details: - Target: N | 2026-01-11 |
| Acquisition of 66.09% stake in Nivian Lifesciences Private Limited Beta Drugs Limited has announced the acquisition of a 66.09% majority stake in Nivian Lifesciences Private Limited. This means Beta Drugs now controls more than two-thirds of Nivian Lifescie | 2026-01-10 |
| Board to consider acquisition of target company equity shares and strategic partnership Beta Drugs Limited announced a Board meeting scheduled for January 9, 2026, to discuss three major corporate actions: 1. ACQUISITION: The company plans to acquire equity shares of another c | 2026-01-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Beta Drugs Ltd. — free to start.
Google PlayApp StoreData updated 2026-09-18.